Drug · DIN 02353261
GABAPENTIN
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 10, 2013; first marketed July 30, 2010.
- Drug Identification Number (DIN)
- 02353261
- Company (DIN owner)
- Sanis Health Inc.Brampton, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Gabapentin N02BF01
- Class
- Human
- Record last updated
- June 23, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| GABAPENTIN | 400 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 9, 2013: NOC 14808Abbreviated New Drug Submission (ANDS) · Licensing agreement between two companies
- July 28, 2010: NOC 11635Abbreviated New Drug Submission (ANDS) · New manufacturer and product name
Other DINs named GABAPENTIN
- DIN 02246314 · Marketed
- DIN 02246315 · Marketed
- DIN 02246316 · Marketed
- DIN 02353245 · Marketed
- DIN 02353253 · Marketed
- DIN 02388200 · Marketed
- DIN 02388219 · Marketed
- DIN 02431289 · Marketed
- DIN 02432072 · Marketed
- DIN 02432080 · Marketed
- DIN 02238671 · Cancelled Pre Market
- DIN 02238672 · Cancelled Pre Market
- DIN 02238673 · Cancelled Pre Market
- DIN 02273853 · Cancelled Post Market
- DIN 02304775 · Cancelled Post Market
- DIN 02304783 · Cancelled Post Market
- DIN 02304791 · Cancelled Post Market
- DIN 02342650 · Cancelled Pre Market
- DIN 02342669 · Cancelled Pre Market
- DIN 02342677 · Cancelled Pre Market